Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1207118
11 June 2021 12:41PM

MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN


DGAP-News: MediClin AG / Key word(s): Personnel
MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN

11.06.2021 / 12:41
The issuer is solely responsible for the content of this announcement.


Dr. Joachim Ramming becomes the new CEO of MEDICLIN

In today's meeting, the Supervisory Board of MEDICLIN Aktiengesellschaft (MEDICLIN) has appointed Dr. Joachim Ramming as member of the Management Board of MEDICLIN and as Chairman of the Board. The PhD economist and health economist will succeed Volker Hippler on August 1, 2021, who is resigning his mandate as CEO and board member of the Company by mutual agreement with the Supervisory Board on June 30, 2021.

"We would like to thank Mr. Hippler for his commitment and the work he has done over the past five years and wish him all the best for his professional and private future. At the same time, we are pleased to have won with Dr. Joachim Ramming a leader with industry experience. Together with his colleagues of the Management Board, he will successfully drive the development of MEDICLIN further with strategic impulses", said Dr. Jan Liersch, Chairman of the MEDICLIN Supervisory Board.

For around 23 years, Dr. Joachim Ramming is active in the healthcare sector. He started his clinical career in 1998 immediately after studying economics as a trainee at RHÖN-KLINIKUM AG, where he learned how to manage a hospital from scratch. Around 20 years of management experience in clinic and hospital management followed, including eight years as managing director of hospitals at Sana Kliniken AG. From July 2015 until his appointment to the Management Board of MEDICLIN, Dr. Joachim Ramming works as managing director or regional managing director for the Asklepios Group, since March 2017 as regional managing director of Asklepios Kliniken Bayern. He is a member of the board of directors of the Association of Private Hospitals in Bavaria. V. (VPKA).

"I am very much looking forward to bring my experience to MEDICLIN and to start to sustainably develop the Company together with my two board colleagues, Tino Fritz and Dr. York Dhein,", said Dr. Joachim Ramming after his appointment and added: "Every crisis is also an opportunity. We must join forces to overcome the consequences of the corona pandemic for MEDICLIN and lead the company into the future. The entire team of the Management Board of MEDICLIN therefore sees the strategic and organizational development as the most urgent task for the coming months."

Dr. Joachim Ramming is a proven expert in the acute sector, he also knows the rehabilitation and medical care center business very well, and will also promote the consistent use of the synergies that arise from the cooperation within the Asklepios Group.

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a Company of the Asklepios Group.



11.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1207118

 
End of News DGAP News Service

1207118  11.06.2021 

fncls.ssp?fn=show_t_gif&application_id=1207118&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.